Ketamine in Acute Brain Injury Patients.

Brain Injuries, Traumatic Clinical Trial

— BIKe  

Official title:

Brain Injury and Ketamine: a Prospective, Randomized Controlled Double Blind Clinical Trial to Study the Effects of Ketamine on Sedative Sparing and Intracranial Pressure in Traumatic Brain Injury Patients.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05097261
• Other study ID #: S60859
• Secondary ID: 2017-004698-15
• Status: Recruiting
• Phase: Phase 4
• Start date: September 6, 2021
• Est. completion date: December 2024

Study information

• Verified date: April 2023
• Source: KU Leuven
• Contact: Liese Mebis, PhD
• Phone: 003216343125
• Email: liese.mebis[@]uzleuven.be
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Although, in the past years, an increasing use of ketamine in Traumatic Brain injury (TBI) has been reported as an adjunct to other sedatives, there is no evidence from randomized clinical trial to support this practice.

The BIKe (Brain Injury and Ketamine) study is a double-blind placebo controlled randomized multicenter clinical trial to examine the safety and feasibility of using ketamine as an adjunct to a standard sedative strategy in TBI patients.

Description:

In this study the effects of ketamine as an adjunct to an standard sedation regime in adult TBI patients will be investigated on the therapy intensity level and intracranial pressure. All patients will receive propofol for sedation to control ICP, to a maximum dose of 4 mg/kg/h. If the ICP is not controlled at the maximum dose of propofol, midazolam will be added, to a maximum dose of 0.3 mg/kg/h, as part of the current standard of care in the Participating Sites. All patients will receive remifentanil, fentanyl or sufentanil infusions for pain relief. The study medication (ketamine or placebo) will be started after randomization.

As part of the current standard of care in the Participating Sites, the decision for decompressive craniectomy and/or barbiturate coma will be taken after multidisciplinary consultation between the treating intensivist and neurosurgeon.

The decision to stop or reduce sedation, lies with the treating physician, based on the level of ICP control, the absence of clinical or radiological signs of deterioration of the neurologic state. In the case of barbiturate coma, the study drug will be discontinued. During and following decompressive craniectomy, the sedative regime (propofol/midazolam/study drug/ opioids) will be continued. In case of suspected or threatening Propofol-Related Infusion syndrome, propofol will be stopped and switched to midazolam. In case of hypertriglyceridemia >200 mg/dL, propofol will be reduced and if necessary, midazolam will be associated to allow control of sedation. During surgical procedures related to the traumatic brain injury or not, the study drug will not be discontinued. The use of open label administration of ketamine is not allowed during the course of the trial, i.e until hospital discharge.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 100
• Est. completion date: December 2024
• Est. primary completion date: June 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Traumatic brain injury patients

• Age >= 18 years

• Admitted to the ICU

• Within 72 hours after admission to the initial hospital:

• ICP monitoring in place (parenchymal probe, ventricular catheter, or both)

• Requiring sedation

Exclusion Criteria:

• Known pregnancy and/or lactation

• Imminent or actual brain death upon inclusion

• Allergy or intolerance to the study medication

• Pre-existing neurocognitive disorders, pre-existing congenital or non-congenital brain dysfunction.

• Inability to obtain informed consent

• Inclusion in an interventional randomised controlled trial of which the PI indicates that co-inclusion specifically in the BIKe study is prohibited.

• Therapy restriction code upon inclusion.

• Porphyria

• Glaucoma

Related Conditions & MeSH terms

• Brain Injuries
• Brain Injuries, Traumatic
• Wounds and Injuries

Intervention

Drug:
• Ketamine
Racemic ketamine® will be administered by continuous infusion in a prefilled 50 ml syringe at a concentration of 50 mg/ml, undiluted. The ketamine dose is 1 mg/kg/h, to a maximum dose of 120 mg/hour, which corresponds to an infusion rate of 0.02 ml/kg/h to a maximum rate of 2.4 ml/h.
• Placebo
Placebo (NaCl 0.9%) will be provided in the same type syringes and administered at the same infusion rate as the IMP (0.02 ml/kg/h to a maximum rate of 2.4 ml/h).

Locations

Country	Name	City	State
Belgium	Imelda Bonheiden	Bonheiden
Belgium	AZ Sint-Jan	Brugge
Belgium	UZLeuven	Leuven
Belgium	CHR de la Citadelle Liège	Liège
Belgium	CHU de Liège	Liège
Belgium	AZ Delta	Roeselare
Belgium	AZ Turnhout	Turnhout

Sponsors (7)

Lead Sponsor	Collaborator
Geert Meyfroidt, MD, PhD	AZ Delta, AZ Sint-Jan AV, AZ Turnhout, Centre Hospitalier Régional de la Citadelle, Imelda Hospital, Bonheiden, University of Liege

Country where clinical trial is conducted

Belgium, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in therapeutic intensity of intracranial pressure (ICP) reducing measures, assessed by the TIL score (Therapy Intensity Level)	The primary efficacy endpoint will be the reduction in daily Therapy Intensity Level (TIL) score, based on the highest score in each item per day until study drug discontinuation (calculated every day on the available data at 7:00 AM). Scales for TIL score range from 0 (minimum) to 38 (maximum). Higher scores are related to worse outcome.	From date of randomization (and start study drug) until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	Intracranial pressure (ICP)	The average of hourly validated intracranial pressure (mmHg) measurements per 24 hours	From date of randomization until study drug discontinuation or or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	Duration of sedation	Total duration of the first period of sedative treatments (propofol, midazolam and/or dexmedetomidine)	defined as the start of the first infusion of either propofol, midazolam and/or dexmedetomidine to the cessation of the last uninterrupted infusion of either propofol, midazolam, opioids and/or dexmedetomidine, assessed up to 6 months.
Secondary	Propofol	Total dose of propofol in mg per 24 hours	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed at ICU discharge, assessed up to 6 months.
Secondary	Mechanical ventilation	Total duration of mechanical ventilation, defined as all types of ventilation where positive end expiratory pressure is applied, expressed in cm H2O (5 cm H2O minimum).	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	Midazolam	Total dose of midazolam in mg per 24 hours	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	ICU length of stay	Length of stay (number of days) in ICU	From ICU admission until ICU discharge (end of stay is defined as application for discharge in the hospital computer system, or death), assessed up to 6 months.
Secondary	Hospital length of stay	Length of stay in hospital (days)	From admission to hospital until end of stay in hospital (dead or alive), assessed up to 6 months.
Secondary	Richmond Agitation-Sedation scale (RASS)	Average daily RASS. Scale ranges from +4 (combative) until -5 (Unarousable).	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	Delirium	Number of delirium-free days, assessed 3 times per day with the Intensive Care Delirium Screening Checklist (ICDSC) or Confusion Assessment Method for the ICU (CAM-ICU delirium scale).	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	eGOS	extended Glasgow Outcome Scale (eGOS)	6 months after the onset of TBI
Secondary	ICU mortality	Mortality during ICU stay	From date of randomization until ICU discharge, assessed up to 6 months.
Secondary	In-hospital mortality	Mortality during hospital stay	From date of randomization until hospital discharge, assessed up to 6 months.
Secondary	Barbiturate coma incidence	The incidence of barbiturate coma	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	Barbiturate coma duration	The duration of barbiturate coma	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.
Secondary	Decompressive craniectomy	The incidence of decompressive craniectomy	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months, assessed up to 6 months.
Secondary	Propofol Infusion Syndrome (PRIS)	Incidence of PRIS documented and diagnosed by the attending physician and defined as: Cardiac manifestations, not explained by a coronary ischemic event: Acute refractory bradycardia leading to asystole, or; ECG: widening of QRS-complex, or Brugada-syndrome-like patterns (particularly Type 1: Coved-type ST-segment elevation >2mm in >1 of V1-V3 followed by a negative T-wave), or ventricular tachy-arrhythmias; Combined with one or more of the following: Unexplained metabolic acidosis (base deficit > 10 mmol/L); Rhabdomyolysis (Creatinine kinase at least five times the upper limit of normal); Hyperlipidaemia (triglyceride levels > 150 mg/dl); Enlarged or fatty liver, apparent on CT or echography; All occurring in patients receiving propofol for > 24h; Diagnosed by the attending physician	From date of randomization until study drug discontinuation or date of death from any cause, whichever came first, assessed up to 6 months.